CLICK “CONTINUE” AT THE BOTTOM OF THE PAGE TO COMPLETE YOUR REGISTRATION TO JOIN US IN NEW ORLEANS, LA.

CAN’T MAKE IT TO NEW ORLEANS? CLICK “CONTINUE” AT THE BOTTOM OF THE PAGE AND SELECT THE LIVE STREAMING OPTION TO PARTICIPATE VIRTUALLY.

Friday, December 11, 2026
Registration and Lunch: 11:30 AM – 12:00 PM CT
Symposium: 12:00 PM – 1:30 PM CT
Location: New Orleans Ernest N. Morial Convention Center
900 Convention Center Blvd
Meeting Room: 343-345 (3rd Floor)

Faculty 

Richard Stone, MD (Chair)
Chief of Staff
Director, Translational Research, Adult Leukemia Program
Dana Farber Cancer Institute
Professor of Medicine 
Harvard University
Boston, MA 

Uma Borate, MBBS, MS
Clinical Professor
Acute Leukemia Clinical Research Director
Hematologic Malignancies at Risk of Leukemic Transformation Program Leader
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Curtis Lachowiez, MD
Assistant Professor of Medicine
Division of Hematology/Medical Oncology
OHSU Knight Cancer Institute
Center for Hematologic Malignancies
Portland, OR 
 

Target Audience 

This activity has been designed to meet the educational needs of hematology/oncology physicians and fellows, pathologists, and oncology advanced practitioners. It may also benefit clinical and oncology pharmacists, oncology nurses, and other HCPs who manage patients with AML.
 

Educational Provider

This activity is provided by Paradigm Medical Communications, LLC.  

 

Supporter Acknowledgment 

This activity is supported by an educational grant from Servier Pharmaceuticals, LLC.    
 

Program Overview

Join this live, in-person symposium to learn how to navigate an increasingly complex therapeutic landscape and optimize outcomes for patients with acute myeloid leukemia (AML). Discover how precision medicine is transforming the treatment of AML. This dynamic program will explore the critical role of IDH1, IDH2, and FLT3 mutations in guiding treatment decisions, highlighting the latest advances in targeted therapies that are reshaping patient care. Through expert insights and practical clinical guidance, attendees will gain confidence in molecular testing, interpreting results, and selecting personalized treatment strategies.
 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe key advances in the treatment of AML that can impact the use of targeted therapy based on recent approvals, emerging data, and ongoing clinical trials 
• Interpret current approaches to the management of IDH-mutant AML, and possible impacts of recent clinical trial data on IDH inhibitors, including novel sequencing and triplet combination sequencing studies
• Determine the appropriate management of patients with FLT3-mutant AML and how recent approvals and emerging data may inform treatment decisions        

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
 

PA Continuing Education 

PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
 

Disclosure of Relevant Financial Relationships 

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.  Disclosure information about relevant financial relationships with ineligible companies (if any) for anyone contributing to content development will be included in materials distributed at the time of the activity. 
 

CME Inquires

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
 

Fee Information

There is no fee required for participation in this activity.
 

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc).  Please contact Paradigm prior to the event at medicaleducation@paradigmmc.org.

Click the "Register Now" button. Once registered, you will receive an email confirmation with the event details.

© 2026 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.